The Prevalence of Gestational Diabetes

Abstract

Software shall not be liable for any claim by you or any other party for damages arising from the use, inability to use, quality, or performance of such Software and Documentation, based upon principles of contract warranty, negligence, strict liability for the negligence of indemnity or contribution, the failure of any remedy to achieve its essential purpose, or otherwise. The entire liability of MicroStrategy, Inc. and your exclusive remedy, shall not exceed, at the option of MicroStrategy, Inc., either a full refund of the price paid, or replacement of the Software. No oral or written information given out expands the liability of MicroStrategy, Inc. beyond that specified in the above limitation of liability. Some states do not allow the limitation or exclusion of liability for incidental or consequential damages, so the above limitation may not apply to you.The information contained in this manual (the Documentation) and the Software are copyrighted and all rights are reserved by MicroStrategy, Inc. MicroStrategy, Inc. reserves the right to make periodic modifications to the Software or the Documentation without obligation to notify any person or entity of such revision. Copying, duplicating, selling, or otherwise distributing any part of the Software or Documentation without prior written consent of an authorized representative of MicroStrategy, Inc. are prohibited. U.S. Government Restricted Rights. It is acknowledged that the Software and Documentation were developed at private expense, that no part is public domain, and that the Software and Documentation are Commercial Computer Software provided with RESTRICTED RIGHTS under Federal Acquisition Regulations and agency supplements to them. Use, duplication, or disclosure by the U.S. Government is subject to restrictions as set forth in subparagraph (c) (1) Other product and company names mentioned herein may be the trademarks of their respective owners.Specifications subject to change without notice. MicroStrategy is not responsible for errors or omissions. MicroStrategy makes no warranties or commitments concerning the availability of future products or versions that may be planned or under development. Patent InformationThis product is patented. One or more of the following patents may apply to the product sold herein: U.S. Patent Nos. 6,154,766, 6,173,310, 6,260,050, 6,263,051, 6,269,393, 6,279,033, 6,567,796, 6,587,547, 6,606,596, 6,658,093, 6,658,432, 6,662,195, 6,671,715, 6,691,100, 6,694,316, 6,697,808, 6,704,723, 6,741,980, 6,765,997, 6,768,788, 6,772,137, 6,788,768, 6,798,867, 6,801,910, 6,820,073, 6,829,334, 6,836,537, 6,850,603, 6,859,798, 6,873,693, 6,885,734, 6,940,953, 6,964,012, 6,977,992, 6,996,568, 6,996,569, 7,003,512, 7,010,518, 7,016,480, 7,020,251, 7,039,165, 7,082,422, 7,113,474, 7,113,993, 7,127,403, 7,174,349, 7,181,417, 7,194,457, 7,197,461, 7,228,303, 7,260,577, 7,266,181, 7,272,212, 7,302,639, 7,324,942, 7,330,847, 7,340,040, 7,356,758, 7,356,840, 7,415,438, 7,428,302, 7,430,562, 7,440,898, 7,486,780, 7,509,671, 7,516,181, 7,...

Evaluation of neonatal and maternal morbidity in mothers with gestational diabetes: a population-based study

“…The recent report published by International Diabetes Federation (IDF) states that one in seven births might be affected by GDM [ 5 ]. At the national level, similar figures have recently been published by Melchior and colleagues, who analysed pregnancies in Germany in the years 2014 and 2015 [ 6 ].…”

Inhibition of IL-1beta improves Glycaemia in a Mouse Model for Gestational Diabetes

“…GDM is defined as glucose intolerance with the onset or first recognition during pregnancy 1 and usually disappears after giving birth 2 . It was estimated that GDM affects 18.4 million pregnancies and 14% of all live births worldwide 2,3 . The incidence of GDM is associated with overweight and increased age of mothers, affecting 26% of pregnant women older than 45 years 3 and 39% of pregnant women with a BMI ≥29 kg/m 2 4 .…”

Visceral Adipose Tissue Inflammatory Factors (TNF-Alpha, SOCS3) in Gestational Diabetes (GDM): Epigenetics as a Clue in GDM Pathophysiology

“…The growing public health problem stemming from the numerous downstream harmful health conditions link to and brought about by overweight and obesity is an important issue in maternal health. The rising prevalence of gestational diabetes mellitus (GDM) is high (>10%) as is overweight and obesity in pregnancy both of which ultimately lead to increased risk for future health complications for mother and child [1][2][3][4][5][6][7][8][9]. The culmination of affluent eating patterns, increased body-mass-index (BMI), and weight gain are key risk factors of developing GDM, which is critically characterized by insulin resistance.…”